The next generation of PPAR drugs: do we have the tools to find them?
Agonists of PPARalpha and PPARgamma are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARbeta/delta are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPAR drug treatments, thus a new generation of safer PPAR drugs are being actively sought after. In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs.
Shearer
Barry G
BG
GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA. barry.g.shearer@FSK.com
Billin
Andrew N
AN
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D015195:Drug Design; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D047493:PPAR alpha / Q000819:agonists; D047495:PPAR gamma / Q000819:agonists; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D012449:Safety
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D047493:PPAR alpha; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors